A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects with Chronic Hepatitis B
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Selgantolimod (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 29 Aug 2020 Results of biomarker analysis assessing potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with selgantolimod presented at The International Liver Congress 2020
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.